Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
View original at finance.yahoo.comMerck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enliciti…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Enlicitide has the potential to help close gaps in achievement of lipid goals in patients with and at risk for cardiovascular events and ultimately help address the ongoing CV epidemic
80% confidenceCardiovascular disease is the leading cause of death globally with approximately 18 million deaths per year worldwide
80% confidenceNearly 70% of people with ASCVD who are treated with lipid-lowering therapies do not reach target LDL cholesterol levels
80% confidenceEnlicitide demonstrated impressive LDL-C reductions with placebo-like safety in the CORALreef Lipids study, underscoring the practice-changing potential of an oral PCSK9 inhibitor
80% confidenceEnlicitide, if approved, adds to physicians' armamentarium to lower LDL-C
80% confidenceEnlicitide has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo
80% confidenceThe majority of patients with atherosclerotic cardiovascular disease do not reach their LDL-C goal despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors
80% confidenceEnlicitide was designed to deliver PCSK9 antibody-like efficacy and specificity in an easy-to-use pill
80% confidenceIn the United States, one person dies every 36 seconds from cardiovascular disease
80% confidence